Ensysce Biosciences, Inc.

NASDAQ (USD): Ensysce Biosciences, Inc. (ENSC)

Last Price

0.483

Today's Change

-0.023 (4.54%)

Day's Change

0.48 - 0.507

Trading Volume

1,138,103

Profile
ENSC

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. D. Lynn Kirkpatrick Ph.D. Dr. D. Lynn Kirkpatrick Ph.D.

Full Time Employees:  7 7

IPO Date:  2018-03-14 2018-03-14

CIK:  0001716947 0001716947

ISIN:  US2936024056 US2936024056

CUSIP:  293602108 293602108

Beta:  0.64 0.64

Last Dividend:  0.00 0.00

Dcf Diff:  0.67 0.67

Dcf:  0.12 0.12

Description

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Address

7946 Ivanhoe Avenue,
La Jolla, CA 92037, US

858 263 4196

http://www.ensysce.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment